Dr Reddy’s announces the launch of Pantoprazole Sodium delayed-released tablets
Dr Reddy’s Laboratories has launched Pantoprazole Sodium Delayed-Released tabletsÂ (20mg and 40mg strengths), a bioequivalent generic version ofÂ Protonix Tablets in the US market.Â The Food & Drug Administration (FDA) approved Dr Reddy’s ANDA for Pantoprazole Sodium Delayed-Released tablets.
Pantoprazole Sodium Delayed-Released tabletsÂ had total U.S. sales of approximately $1.8 billion for the twelve months ending September 30, 2010 according to IMS Health.Â Both strengths of Dr Reddy’s Pantoprazole Sodium Delayed-Released tabletsÂ are available in 90 count bottles.
Dr Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Â Pharmaceutical Services and Active Ingredients,Â Global GenericsÂ andÂ Proprietary ProductsÂ â Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Hypoxia Result in Permanent DNA Changes
Researchers at the University of California, San Diego School of Medicine have proven that the genomes of flies exposed to long-term hypoxia are changed to permanently affect gene expression. Their findings are published online by the journal of theÂ Proceedings of the National Academy of Sciences (PNAS). They may lead to new targets for development of therapies for hypoxia-induced disease in humans.
The study was conducted at Rady Children’s Hospital-San Diego, Department of Pediatrics. Because cellular mechanisms in fruit flies are very similar to those in human cells, the scientists studied populations of Drosophila melanogasteÂ generated through long-term laboratory selection over 200 generations. These flies are capable of tolerating severe, normally fatal hypoxia, and pass their hypoxia tolerance trait to subsequent generations â the trait persisting even in the absence of hypoxic stress, which suggests a genetic rather than a physiological mechanism is at play in adaption.
Using high-throughput screening, the researchers compared the genomics of these flies with those of normal controls, and were able to identify a number of specific DNA regions, mostly on the X-chromosome, related to hypoxia resistance.
Imaging Procedure to Diagnose Alzheimer’s
A new type of molecular imaging procedure may be capable of detecting the presence of beta-amyloid, a protein linked to Alzheimer’s disease. This preliminary research is conducted by Avid Radiopharmaceuticals.
The study provides evidence that a molecular imaging procedure can identify beta-amyloid pathology in the brain, a development that can help to identify Alzheimer’s disease.
Florbetapir-PET imaging combines florbetapir F 18, a diagnostic chemical that binds to beta-amyloid, with a PET scan. The researchers used this technique to measure the beta-amyloid levels of 35 patients near the end of their lives, and compared this with beta-amyloid levels after death as determined by autopsy.
An analysis of images and other data indicated a correlation between florbetapir-PET images and the levels of beta-amyloid pathology at autopsy.
In addition, the Florbetapir-PET scans matched the autopsy results 96 percent of the time. Key- Imaging,Â Â Diagnose , Alzheimers, Florbetapir.